{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:44:39Z","timestamp":1790815479379,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Essential medicine is a vital component to assure universal access to quality healthcare. However, the trend of affordability to essential medicines in China and its regional differences were not yet fully understood. This study aimed to systematically evaluate the price and affordability of essential medicines, their progress, and regional distribution in China in the last decades.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    We searched seven databases and three websites for potentially eligible studies from inception until March 2022. Studies on the price and affordability of essential medicines investigated in China were included. Median and interquartile range (IQR) was used to describe the price and affordability of essential medicines, and compared in three periods, before 2009, from 2009 to 2014, and from 2015 to 2019. Subgroup analysis was performed to examine the price and affordability by regions, health facilities, and ATC categories of medicines. The study was registered with PROSPERO (CRD42022310173).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 65 studies including 11,639 health facilities investigated between 2006 and 2019 were included in this review. Median price ratios (MPR) and affordability of essential medicines were reported in 44 studies and 50 studies, respectively. The median MPRs of essential medicines in China was 1.59 (IQR: 5.39), with a tendency to rise first and then fall from 2006 to 2019. And the median affordability was equal to 0.88 (IQR: 2.58) days\u2019 wage of the lowest paid unskilled government worker, but steadily rose from 2006 to 2019. Subgroup analysis showed that the affordability in the western region (1.40, IQR: 2.88), urban area (0.95, IQR: 2.80), private sector (0.90, IQR: 2.30), of originator brands (OB) (2.90, IQR: 6.68), and antineoplastic and immunomodulating agents (5.68, IQR: 56.47) were worse than their counterparts.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The prices of essential medicine were higher than international level, the overall affordability of essential medicines in China is acceptable but poor in the western region, for OB drugs and anti-cancer medicines. Further national essential medicine policies are needed to reduce regional disparities and improve the affordability of expensive drugs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Systematic Review Registration:<\/jats:bold>\n                    <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/#recordDetails<\/jats:ext-link>\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1153972","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:54:53Z","timestamp":1683248093000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["The price and affordability of essential medicines, progress and regional distribution in China: a systematic review"],"prefix":"10.3389","volume":"14","author":[{"given":"Zheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingchen","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imti","family":"Choonara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"Cd005979","DOI":"10.1002\/14651858.CD005979.pub2","article-title":"Pharmaceutical policies: Effects of reference pricing, other pricing, and purchasing policies","volume":"2014","author":"Acosta","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s40273-013-0095-9","article-title":"The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries","volume":"31","author":"Babar","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"B3","first-page":"1","article-title":"Financial burden of medical care: A family perspective","volume":"142","author":"Cohen","year":"2014","journal-title":"NCHS Data Brief."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0241761","DOI":"10.1371\/journal.pone.0241761","article-title":"Availability, prices and affordability of essential medicines in Zhejiang Province, China","volume":"15","author":"Dong","year":"2020","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0171284","DOI":"10.1371\/journal.pone.0171284","article-title":"Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases","volume":"12","author":"Ewen","year":"2017","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"Cd008654","DOI":"10.1002\/14651858.Cd008654","article-title":"Pharmaceutical policies: Effects of restrictions on reimbursement","volume":"2010","author":"Green","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0182613","DOI":"10.1371\/journal.pone.0182613","article-title":"Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks","volume":"12","author":"Gronde","year":"2017","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12939-018-0870-5","article-title":"A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals","volume":"17","author":"Guan","year":"2018","journal-title":"Int. J. Equity Health"},{"key":"B9","first-page":"2224","article-title":"Empirical study on essential medicine price in China [Chinese]","volume":"24","author":"Guan","year":"2013","journal-title":"China Pharm."},{"key":"B10","unstructured":"Survey & related reports2021"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e015302","DOI":"10.1161\/jaha.119.015302","article-title":"Access to cardiovascular disease and hypertension medicines in developing countries: An analysis of essential medicine lists, price, availability, and affordability","volume":"9","author":"Husain","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B12","first-page":"2777","article-title":"Degree of coordination between primary care resource allocation and economic development in Eastern,Central and western China [Chinese]","volume":"24","author":"Li","year":"2021","journal-title":"Chin. General Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.14055\/j.cnki.33-1056\/f.2022.01.002","article-title":"Results and analysis of national health accounts in 2020 in China [Chinese]","volume":"39","author":"Li","year":"2022","journal-title":"Health Econ. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12913-021-06533-x","article-title":"Trends and determinants of catastrophic health expenditure in China 2010-2018: A national panel data analysis","volume":"21","author":"Liu","year":"","journal-title":"BMC Health Serv. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"618046","DOI":"10.3389\/fmed.2021.618046","article-title":"Systematic review of the effect of a zero-markup policy for essential drugs on healthcare costs and utilization in China, 2015-2021","volume":"8","author":"Liu","year":"","journal-title":"Front. Med. (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"944540","DOI":"10.3389\/fphar.2022.944540","article-title":"Changing characteristics of pharmaceutical prices in China under centralized procurement policy: A multi-intervention interrupted time series","volume":"13","author":"Long","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"Cd007017","DOI":"10.1002\/14651858.CD007017.pub2","article-title":"Pharmaceutical policies: Effects of cap and co-payment on rational use of medicines","volume":"2015","author":"Luiza","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1186\/s12889-021-11573-3","article-title":"Urban-rural differences in healthcare utilization among beneficiaries in China's new cooperative medical scheme","volume":"21","author":"Luo","year":"2021","journal-title":"BMC Public Health"},{"key":"B19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/xeb.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int. J. Evid. Based Healthc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"628744","DOI":"10.3389\/fpubh.2021.628744","article-title":"Availability, affordability, access, and pricing of anti-cancer medicines in low- and middle-income countries: A systematic review of literature","volume":"9","author":"Ocran Mattila","year":"2021","journal-title":"Front. Public Health"},{"key":"B21","unstructured":"Comments on conducting consistency assessment of the quality and efficacy of generic medicines2016"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1423","DOI":"10.1016\/s2214-109x(22)00330-8","article-title":"The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: A systematic review","volume":"10","author":"Stolbrink","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.3390\/ijerph19084578","article-title":"Impacts of national drug price negotiation on expenditure, volume, and availability of targeted anti-cancer drugs in China: An interrupted time series analysis","volume":"19","author":"Sun","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B24","volume-title":"Ensure healthy lives and promote well-being for all at all ages","year":"2020"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e002086","DOI":"10.1136\/bmjgh-2019-002086","article-title":"Towards universal health coverage: Lessons from 10 years of healthcare reform in China","volume":"5","author":"Tao","year":"2020","journal-title":"BMJ Glob. Health"},{"key":"B26","unstructured":"Guidelines for deepening the reform of health care system2009"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0255742","DOI":"10.1371\/journal.pone.0255742","article-title":"Availability, affordability and price components of insulin products in different-level hospital pharmacies: Evidence from two cross-sectional surveys in Nanjing, China","volume":"16","author":"Wang","year":"2021","journal-title":"PLoS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"925910","DOI":"10.3389\/fpubh.2022.925910","article-title":"Government health expenditure, economic growth, and regional development differences-analysis based on a non-parametric additive model","volume":"10","author":"Wang","year":"2022","journal-title":"Front. Public Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0009766","DOI":"10.1371\/journal.pntd.0009766","article-title":"Prevalence and characteristics of malaria among COVID-19 individuals: A systematic review, meta-analysis, and analysis of case reports","volume":"15","author":"Wilairatana","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B30","unstructured":"The selection of essential medicines2002"},{"key":"B31","volume-title":"Measuring medicine prices, availability, affordability and price components","year":"2008"},{"key":"B32","volume-title":"Ten years in public health, 2007\u20132017: Report by dr margaret chan, director-general","year":"2017"},{"key":"B33","volume-title":"WHO guideline on country pharmaceutical pricing policies","year":"2020"},{"key":"B34","volume-title":"World health statistics 2022: Monitoring health for the SDGs, sustainable development goals","year":"2022"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e019442","DOI":"10.1136\/bmjopen-2017-019442","article-title":"Impact of the new cooperative medical scheme on the trend of catastrophic health expenditure in Chinese rural households: Results from nationally representative surveys from 2003 to 2013","volume":"8","author":"Xie","year":"2018","journal-title":"BMJ Open"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e005519","DOI":"10.1136\/bmjgh-2021-005519","article-title":"Lowering drug prices and enhancing pharmaceutical affordability: An analysis of the national volume-based procurement (NVBP) effect in China","volume":"6","author":"Yuan","year":"","journal-title":"BMJ Glob. Health"},{"key":"B37","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12913-021-06408-1","article-title":"Economic status and catastrophic health expenditures in China in the last decade of health reform: A systematic review and meta-analysis","volume":"21","author":"Yuan","year":"","journal-title":"BMC Health Serv. Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.3390\/ijerph16193728","article-title":"Availability, price and affordability of anticancer medicines: Evidence from two cross-sectional surveys in the Jiangsu province, China","volume":"16","author":"Zhu","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/17512433.2020.1713749","article-title":"The interpretation of China national essential medicines list 2018","volume":"13","author":"Zuo","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1153972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:55:04Z","timestamp":1683248104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1153972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":39,"alternative-id":["10.3389\/fphar.2023.1153972"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1153972","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"article-number":"1153972"}}